Sophia Genetics (SOPH) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.30
- EPS estimate
- −$0.21
- EPS surprise
- −42.86%
- Revenue surprise
- +7.32%
- Revenue
- $23.3M
- Revenue estimate
- $21.7M
- Reported
- Aug 4, 2026
Sophia Genetics reported Q2 2026 results on August 4, 2026. The company posted a loss of $0.30 per share, wider than the $0.21 loss analysts expected, a 42.86% miss. Revenue of $23.3 million came in 7.32% above the $21.7 million estimate. Compared with Q2 2025, the loss per share narrowed from $0.33, and revenue grew about 27% from $18.3 million.
All 20 quarters in the table were losses, between $0.17 and $0.40 per share. Revenue, by contrast, has climbed fairly steadily, from $10.4 million in Q3 2021 to a high of $23.3 million in the latest quarter. Yearly revenue rose from $47.6 million in 2022 to $77.3 million in 2025, while annual losses stayed between $0.95 and $1.26 per share. The first half of 2026 brought $45.0 million in revenue, up about 25% on the first half of 2025. Sophia Genetics beat the EPS estimate in eight of the last 20 quarters, but in none of the last eight.
Q3 results arrived between November 4 and November 10 in each of the past five years, so the next report is likely in early November 2026. It will show whether revenue keeps growing and the loss narrows.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.21 | −$0.30 | −42.86% | $23.3M | SEC |
| Q1 2026 | May 5, 2026 | −$0.23 | −$0.27 | −16.13% | $21.7M | SEC |
| Q4 2025 | Mar 3, 2026 | −$0.24 | −$0.28 | −17.89% | $21.7M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.23 | −$0.30 | −30.43% | $19.5M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.21 | −$0.33 | −54.21% | $18.3M | SEC |
| Q1 2025 | May 6, 2025 | −$0.22 | −$0.26 | −16.44% | $17.8M | SEC |
| Q4 2024 | Mar 4, 2025 | −$0.21 | −$0.23 | −12.20% | $17.7M | SEC |
| Q3 2024 | Nov 5, 2024 | −$0.22 | −$0.28 | −26.13% | $15.9M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.27 | −$0.23 | +13.53% | $15.8M | SEC |
| Q1 2024 | May 7, 2024 | −$0.25 | −$0.21 | +14.29% | $15.8M | SEC |
| Q4 2023 | Mar 5, 2024 | −$0.22 | −$0.37 | −70.11% | $17.0M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.30 | −$0.21 | +30.00% | $16.3M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.29 | −$0.33 | −12.28% | $15.1M | SEC |
| Q1 2023 | May 9, 2023 | −$0.30 | −$0.31 | −1.81% | $14.0M | SEC |
| Q4 2022 | Mar 7, 2023 | −$0.34 | −$0.17 | +50.28% | $13.4M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.36 | −$0.30 | +17.42% | $11.6M | — |
| Q2 2022 | Aug 9, 2022 | −$0.39 | −$0.39 | +0.84% | $11.7M | — |
| Q1 2022 | May 10, 2022 | −$0.33 | −$0.40 | −21.36% | $10.9M | — |
| Q4 2021 | Mar 15, 2022 | −$0.36 | −$0.28 | +21.50% | $10.9M | — |
| Q3 2021 | Nov 10, 2021 | −$0.36 | −$0.30 | +15.90% | $10.4M | — |
Quarterly revenue
Frequently asked questions
When did Sophia Genetics (SOPH) last report earnings?
Sophia Genetics last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did SOPH beat earnings estimates?
No. Sophia Genetics reported EPS of −$0.30 for Q2 2026 against a −$0.21 estimate — a 42.86% miss.
How much revenue did SOPH report last quarter?
Sophia Genetics reported $23.3M in revenue for Q2 2026, against a consensus estimate of $21.7M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.